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Turbuhaler has a very high resistance hence patient inhalation flow when using it would
be low.
The total emitted dose (TED) of 500 mg terbutaline sulphate from a Bricanyl Turbuhaler
was determined using a range of inhalation flows (10e60 L min1) with inhalation volume
of 2 and 4 L using a DPI sampling apparatus after one and two inhalations.
The relative lung and systemic bioavailability of terbutaline from Bricanyl Turbuhaler
when used by healthy subjects and COPD patients were determined after one and two inha-
lations at slow and fast inhalation flows using a novel urinary terbutaline pharmacokinetic
method.
The TED resulted from the one and two inhalations increased significantly (p < 0.05) with
the increase of the inhalation flow at both 2 and 4 L inhalation volumes. The relative lung
and systemic bioavailability after one inhalation at fast inhalation flow were significantly
higher (p < 0.01) than at slow inhalation flow in both healthy subjects and patients. Also
the healthy subjects results were significantly higher (p < 0.05) than the COPD patients after
one inhalation.
However after two inhalations there was no significant difference between slow and fast
inhalation flow or healthy subjects and COPD patients.
Hence it is essential to inhale twice and as deep and hard as possible from each dose of
Turbuhaler for patients with low inspiratory flow and limited inhalation volume as they
may not receive much benefit from one inhalation.
ª 2009 Elsevier Ltd. All rights reserved.nical Pharmacy, Faculty of Pharmacy, University of Beni Suef, Beni Suef, Egypt. Tel.: þ20 11 826 1953;
yahoo.com
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All currently marketed dry powders inhalers need internal
turbulent energy during inhalation to generate an emitted
dose containing particles with the potential for lung
deposition. For some dry powder inhalers the dependence
of drug delivery on inhalation flow rate is very small
whereas for others there is a steep increase in dose
emission with the speed of the inhalation flow. The Tur-
buhaler has previously been shown to be a device of high
resistance,1 which also demonstrates in vitro flow
dependent dose emission.2 Owing to its high airflow
resistance, it is difficult to achieve a peak inhalation flow
rate 60 L min1 through Turbuhaler. The variation of the
emitted dose is a very important factor that could affect
the clinical response and side effects. Two gamma scin-
tigraphy studies using radiolabelled short acting b2 agonist
and budesonide in a Turbuhaler showed that total lung
deposition can vary with the inhalation flow.3,4 All the
studies focus on inhalation flow of greater than 30 L min1
through a Turbuhaler, however during routine use some
patients do not achieve that 30 L min1 required for the
delivery of the dose.5
Pharmacopoeia tests for dose emission recommend using
an inhalation flow equivalent to a pressure drop of 4 kPa
across the inhaler with 4 L inhalation volume. This corre-
sponds to a peak inhalation flow rate of 53 L min1 when
using a Turbuhaler.1 Whereas most COPD patients will
inhale around 2 L as inhalation volume and some may even
inhale at a very low inhalation flow that cannot produce
4 kPa pressure drops across the inhaler.6 To overcome this
problem the manufacture leaflet of most of the dry powder
inhalers recommend the patient to inhale the dose from the
inhaler as hard and deep as possible.
A novel salbutamol pharmacokinetic method has shown
that the amount of salbutamol excreted 30 min post dosing
is an index of the total lung deposition (lung bioavailability
of inhaled dose) and the amount of salbutamol excreted
24 h post dosing is an index of the systemic bioavailability
of inhaled dose.7 The novel urinary salbutamol pharmaco-
kinetic method7 was extended to terbutaline8 so that the
patient’s salbutamol prescription can be maintained.
Hence terbutaline dosage form can be used as the study
preparation for patient studies.
The aim of this study were to determine the terbutaline
sulphate total emitted dose (TED) after one and two inha-
lations from a Turbuhaler using different peak inhalation
flows with inhalation volumes of 2 and 4 L. The generated in
vitro data is to be linked to the in vivo fate of terbutaline
sulphate from Bricanyl Turbuhaler after one and two inha-
lations in healthy subjects and COPD patients inhaling at
slow and fast inhalation flow.
Method
Total emitted dose
The total emitted dose (TED) was determined using inha-
lation flows of 10e60 L min1 and 2 and 4 L inhalation
volume using a DPI sampling apparatus (Copley Scientific
Ltd, UK) after one and two inhalations.The dose of 500 mg terbutaline sulphate emitted from
a Bricanyl Turbuhaler was determined using the dose
emission method described in the US Pharmacopoeia 20059
except that a range of flows have been used instead of the
flow that produces 4 kPa pressure drop across the device.
For each determination two dose emission apparatus were
used so that the dose emitted from the first inhalation and
a second inhalation can be measured separately. The
emitted dose in each apparatus was then summed to give
the two inhalations TED value.
The emitted dose from the Bricanyl Turbuhaler (labeled
as a nominal dose of 500 mg terbutaline sulphate per puff,
AstraZeneca, UK) was measured using a DPI sampling
apparatus with a critical flow controller model TPK (Copley
Scientific Ltd, UK). The final filter was a 47 mm A/E fiber
glass filter discs (Pall Corporation, USA). Vacuum flow
through the apparatus was provided by a GAST pump (Brook
Crompton, UK). The standard compendial methodology of
the USP at an inhalation volume of 4 L and at pressure drop
of 4 kPa was modified to allow determination at different
flows and volumes. The inhalation flow through the
mouthpiece of the Turbuhaler was set at 10, 20, 30, 40, 50
and 60 L min1 with flow-duration of 24, 12, 8, 6, 4.8 and 4 s
respectively to allow an inhaled volume of 4 L of air to be
drawn through the inhaler and 12, 6, 4, 3, 2.4 and 2 s
respectively to allow an inhaled volume of 2 L of air to be
drawn through the inhaler. The flow was measured by an
electronic digital flow meter (MKS Instruments, USA). Par-
afilm M laboratory film (Pechiney Plastic Packaging, USA)
was used to seal the apparatus.
Each inhaler was inserted tightly into the mouthpiece
and aligned along the horizontal axis. The emitted dose
from the Bricanyl Turbuhaler was measured by collecting
one individual dose at different inhalation flows. For each
determination the Turbuhaler was loaded to deliver a dose,
according to the instructions in the patient information
leaflet. For each inhalation flow, the emitted dose of 10
separate, single doses, throughout the life of each inhaler,
were determined (nZ 10). For this procedure a switching
system was used to produce sonic flow conditions, as rec-
ommended by the Pharmacopoeial Methods.9e11 Doses not
required were discharged to waste using a flow of 90 L
min1 for a 16 s vacuum period to clean the Turbuhaler.
This flow has been reported to clear the Turbuhaler from
residue.12 Following dose emission into the apparatus, the
sampling unit was washed with 25% acetonitrile and the
filter was completely submerged in 25% acetonitrile and
then sonicated for 3 min (preliminary analysis revealed that
this procedure removes all drug entrained on the filter).
The amount of drug was determined by high performance
liquid chromatography. The method used was a Water
Spherisorb C18, ODS1 column through which a mobile phase
of 5 mM potassium dihydrogen orthophosphate-acetonitrile
(75:25), adjusted to pH 2.5 with orthophosphoric acid, was
pumped at 1 ml min1. The spectrofluorometric detector
(RF-551, Shimadzu, Japan) was set at an excitation/emis-
sion of 267/313 nm and bamethane hemisulphate (Sigma,
UK) was the internal standard. The limit of detection was
10.9 mg L1 and the lower limit of quantification was
33.1 mg L1. The total dose emitted was the amount
deposited in the plastic dose sampling apparatus and the
final filter.
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The study was a four-way cross-over on 4 different days
with 7 days washout period (one inhalation fast flow, one
inhalation slow flow, two inhalations fast flow, two inha-
lations slow flow), with a total dose of 1000 mg of terbuta-
line sulphate on each occasion.
An ethical approval was obtained from the University of
Beni Suef for the health subjects study and all volunteers
gave signed informed consent. Twelve healthy non-smoking
volunteers (six females), older than 18 years with a mean
FEV1 > 90% of predicted, agreed to inhale two doses
through two Bricanyl Turbuhalers (labeled as 500 mg ter-
butaline sulphate nominal dose, AstraZeneca, UK), using
slow and fast inhalation flows.
A local hospital research ethics committee approval was
obtained for the patients study. COPD patients, with FEV1 less
then 50% of predicted at screening, were asked to take part in
this study. If they accepted to take part in the study, consent
was obtained from each patient. If at any time the patient
requested to quit the study then they were withdrawn
together with all their data and their samples were disposed.
For each patient, the FEV1 was measured on the study day
before taking the dose resulting in four FEV1 for each patient.
The healthy subjects and the patients were trained how
to inhale using a slow inhalation flow (30 L min1) and also
a fast inhalation flow (60 L min1) with aid of the In-Check
Dial. They all received training on how to use a Turbuhaler.
Doses were loaded for the subject before use according to
the patient information leaflet. Subjects were trained to
breathe out gently but not breathe out through the inhaler,
prepare a dose for inhalation as recommended in the
patient information leaflet, then place the mouthpiece
between their lips and inhale through their mouth,
according to the inhalation flow to be used. Inhalation
continued till their lungs were full (total lung capacity) and
they then removed the Turbuhaler from their mouth and
held their breath for 10 s before breathing out slowly fol-
lowed by normal breathing. Each subject inhaled two doses
from two separate Bricanyl Turbuhalers using either a slow
or a fast inhalation flow maneuvers in random order.
The use of the two Turbuhalers was to avoid the inha-
lation of the residual part that would remain in the Tur-
buhaler from first dose. The residual part was later
removed from the Turbuhaler by discharging to waste using
a very high inhalation flow (90 L min1) for 16 s. This testing
maneuver was to measure the bioavailability of one
inhalation.Table 1 The mean (SD) total emitted dose % of 500 mg terbuta
Inhalation flow (L/min) Volume
2 L
One inhalation Two in
10 21.4 (13.5) 33.7 (
20 45.5 (7.9) 50.5 (
30 47.5 (6.5) 52.5 (
40 52.3 (6.5) 56.5 (
50 60.8 (11.7) 64.1 (
60 67.0 (4.8) 69.9 (To do a two inhalations test, the patient was asked to do
the same maneuver of one inhalation at slow and fast
inhalation flow but inhale twice from each inhaler.
On each study day subjects were allowed to have a light
breakfast and no caffeine or alcohol containing drinks for at
least 12 hbefore dosing. According to the novel urinary ter-
butaline method,8 immediately before each study dose each
subject voided their urine then provided a urine sample
30 min after the start of the first dose and cumulatively
collected their urine for 24 h. The volumes of urine samples
were measured and assayed for the urinary terbutaline
concentration using an HPLC-fluorescence spectrophotom-
etry. The terbutaline was extracted from the urine samples
together with Bamethane (Sigma, UK) as internal standard
using solid phase extraction, Isolute HCX 130 mg 10 ml XL
cartridge andOasis HLB 30 mg cartridge, then injected in the
HPLC system. The method used was an ODS 5 mm,
(4.6  250 mm, Zorbax, Phenomenex) C-18 HPLC column
with a (4 mm  3 mm, Phenomenex); C-18 (ODS) guard
column. Both were maintained at 30 C. The mobile phase
was acetonitrileemethanoletetrahydrofuraneethyl aceta-
teebuffer 5:5:5:5:80% v/v. The buffer was 40 mM phosphate
buffer and 27.5 mM sodium dodecyl sulphate with pH 6.75
adjusted using 10 mM KOH. Fluorescence detection set with
an excitation/emission of 267/313 nm.The limit of detection
(LOD) and lower limit of quantification (LLOQ) for terbutaline
was 24.2 and 73.4 mg L1, respectively.
Statistical analysis
A one-way analysis of variance (ANOVA) test with the
application of the Bonferroni correction was used to
compare the total emitted dose (TED) at different inhala-
tion flows using SPSS V15.0 (SPSS Inc., Chicago, IL).
A two-way analysis of variance (ANOVA) test was used to
compare the urine samples at slow and fast inhalation flows
from healthy subjects and COPD patients using SPSS V15.0
(SPSS Inc., Chicago, IL).
Results
In vitro
The TED (nZ 10 doses) of terbutaline sulphate from the
Turbuhaler at different inhalation flows are shown in
Table 1. The amounts are expressed as a % of the 500 mg
terbutaline sulphate nominal dose.line sulphate at different inhalation flow.
4 L
halations One inhalation Two inhalations
23.6) 34.0 (7.4) 36.4 (11.2)
11.5) 48.0 (8.3) 64.9 (2.4)
13.9) 56.0 (11.1) 70.5 (4.4)
6.1) 64.8 (8.0) 68.9 (6.5)
11.5) 72.4 (14.5) 72.5 (7.9)
5.3) 76.6 (6.4) 77.3 (3.5)
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inhalations increased significantly (p < 0.05) with the
increase of the inhalation flow at both 2 and 4 L inhalation
volumes.
The TEDs resulted from 2 L inhalation volume and one
inhalation were significantly lower than from 4 L inhalation
volume and one inhalation at all studied inhalation flows
(p < 0.05).
In vivo
Twelve (six females) healthy non-smoking subjects with
a mean (SD) age, weight and height of 29.2 (4.8) years, 66.3
(11.8) kg and 170.5 (7.4) cm, respectively and FEV1 of 96.1
(3.7) % of predicted completed the DPI flow effect healthy
subject study.
Twelve (six females) COPD patients with a mean (SD)
age, weight and height of 64.8 (12.4) years, 81.2 (12.7) kg
and 167.9 (14.5) cm, respectively and FEV1 of 46.1 (7.7) %
of predicted completed the DPI flow effect patient study.
The mean and individual FEV1 for healthy subjects and
patients are shown in Table 2. The mean (SD) urinary
excretion of terbutaline post inhalation of two doses of
500 mg terbutaline sulphate from the Bricanyl Turbuhaler at
slow and fast inhalation flows are shown in Table 3 and
Figures 1 and 2.
Statistical analysis of the data produced from one
inhalation revealed that the mean (SD) terbutaline
excreted 30 min and 24 h post start of the inhalation from
healthy subjects and COPD patients after slow inhalation
flow were significantly lower than after fast inhalation flow
(p < 0.01). However after two inhalations there was no
significant difference between slow and fast inhalation in
healthy subjects and COPD patients.
At one inhalation COPD patient excreted significantly
lower amount of terbutaline than healthy subject at slow
(p < 0.05) and fast (p < 0.01) inhalation flow. However
after two inhalations there was no significant difference




Day 1 Day 2 Day 3 Day
1 45.0 39.0 41.0 55.0
2 46.0 40.0 35.0 54.0
3 41.0 55.0 57.0 41.0
4 43.0 32.0 56.0 56.0
5 43.0 52.0 34.0 45.0
6 41.0 55.0 56.0 32.0
7 48.0 35.0 42.0 53.0
8 45.0 55.0 42.0 35.0
9 41.0 55.0 56.0 51.0
10 44.0 51.0 35.0 41.0
11 47.0 53.0 55.0 56.0
12 46.0 51.0 40.0 40.0
Mean (SD) 44.2 (2.4) 47.8 (8.7) 45.8 (9.4) 46.6In COPD patients after one fast inhalation, the mean (SD)
terbutaline excreted 30 min and 24 h post start of the
inhalation were significantly lower than after two inhala-
tions (p < 0.01). However there was no significant differ-
ence in healthy subjects.
Discussion
It has been previously shown that there is a difference in
the resistance between the types of dry powder inhaler
devices available on the market.13 Some have low resis-
tance, others have medium resistance and the remainder
have high resistance to inspiratory effort. If the resistance
is high, then a greater inspiratory effort is required to
generate the same inhalation flow achieved with a lower
resistance.
The in vitro results presented here show that the ter-
butaline sulphate from Turbuhaler has a flow dependent
dose emission property after one inhalation at 2 or 4 L
inhalation volume, confirming the results of the previously
published literatures.2,12,14e17 The flow dependent dose
emission property could be due to the incomplete de-
aggregation of the drug from the device at low flow as was
previously shown by de Boer et al. (1996).18
However this flow dependant dose emission property
decreased after two inhalations. Table 1 shows that the two
inhalations increased the TED at all inhalation flows and
decrease the variation between the TEDs resulted from
different inhalation flows. Previous studies have shown that
some children,5 adult asthmatic19,20 and COPD21,22 patients
have problems achieving the recommended optimal4 inha-
lation flow of 60 L min1 through a Turbuhaler. Hence to get
the most benefit of the inhaled dose it would be better to
inhale twice from Turbuhaler mainly for those patients with
small inhalation volume and cannot produce a high inha-
lation flow. However at inhalation flows of 50 and 60 L
min1 there was no significant difference between the TEDs
produced from one inhalation and two inhalations. Hence it
is very important when using a Tubuhaler to inhale as fastnt and health subject.
Healthy subject





45.0 (7.1) 1 99.0
43.8 (8.2) 2 95.0
48.5 (8.7) 3 99.0
46.8 (11.6) 4 98.0
43.5 (7.4) 5 90.0
46.0 (11.6) 6 99.0
44.5 (7.8) 7 98.0
44.3 (8.3) 8 97.0
50.8 (6.8) 9 92.0
42.8 (6.7) 10 99.0
52.8 (4.0) 11 89.0
44.3 (5.3) 12 98.0
(8.6) 46.1 (7.7) Mean (SD) 96.1 (3.7)
Table 3 Mean (SD) urinary excretion of terbutaline 30 min and over the first 24 h post dosing of two 500 mg terbutaline
sulphate doses from the Turbuhaler using slow and fast inhalation flows [expressed in mg] (nZ 12).
Inhalation flow Healthy subjects COPD patients
30 min 24 h 30 min 24 h
One inhalation Slow 4.9 (3.9) 222.2 (191.3) 4.2 (2.8) 180.5 (102.8)
Fast 15.9 (8.2) 502.5 (194.6) 6.8 (5.9) 269.7 (215.2)
Two inhalations Slow 14.4 (7.2) 495.3 (191.6) 12.7 (6.3) 475.6 (187.7)
Fast 17.4 (8.9) 531.6 (199.8) 16.4 (8.5) 516.8 (199.9)
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overcome the lung volume limitation of some patients.
This is consistent with the most desirable inhalation flow
for use with the Turbuhaler which has been reported to be
60 L min1,3,23 and the patient information leaflet which
instructs the patients to inhale as deep and hard as they can
during inhalation. When patients use the recommended
inhalation technique for a Turbuhaler and inhale as deep and
hard as they can, then their inhalation flow through this
devicewill determine the amount deposited in their lung. An
addition to the patient information leaflet of the Turbuhaler
can be recommended, to ‘inhale twice when taking each
dose’, as this may increase the dose delivered to the lung.
Previously the TED and the fine particle dose (FPD) were
determined from terbutaline sulphate Turbuhaler over the
inhalation flow rates of 10e60 L min1 with a 4 L inhalation
volume. At inhalation flow rate of 10, 20, 30, 40, 50 and
60 L min1 the mean (SD) FPD were 1.6 (0.8), 1.9 (0.7), 5.9
(2.5), 12.8 (4.3), 24.2 (1.9) and 36.5 (5.1) % of the 500 mg
terbutaline sulphate nominal dose, respectively.24 This
study showed that the terbutaline sulphate from Tur-
buhaler has a flow dependent dose emission property and
flow dependent fine particle dose characteristic. The TED
and FPD were significantly increased with the increase ofFigure 1 Mean (SD) [nZ 12] and the individual amounts of urina
one inhalation; (B) over the first 24 h post one inhalation; (C) 30
inhalations of two doses of 500 mg terbutaline sulphate dosing fromthe flow (p < 0.001). However the flow had a more
pronounced effect on the FPD than the emitted dose, thus,
a faster inhalation increases the respirable amount more
than it increases the emitted dose.24
The flow dependent dose emission characteristics have
been reported from the Turbuhaler containing budeso-
nide,2,16 salbutamol,17 terbutaline14,15 and a combination
of budesonide and formoterol.12 However those studies
were made using an inhalation flow above 30 L min1 and
one inhalation only.
The data represented here suggests that below 30 L
min1 the TED falls off very sharply after one inhalation
with 2 or 4 L inhalation volumes. This suggests that 30 L
min1 is the minimum flow that should be used through the
terbutaline sulphate Turbuhaler. However the TED
increased even at inhalation flows lower than 30 L min1
when using two inhalations.
A novel pharmacokinetic method that have been previ-
ously developed for Salbutamol7 and validated for terbu-
taline8 was used here to compare the different inhalation
maneuvers. As mentioned before, the previously validated
terbutaline pharmacokinetic method had shown that the
amount of terbutaline excreted in urine 30 min post dosing
is an index of the amount of terbutaline deposited in thery terbutaline excreted from healthy subjects (A) 30 min post
min post two inhalations; and (D) over the first 24 h post two
the DPI using a fast and slow inhalation flows.
Figure 2 Mean (nZ 12) and the individual amounts of urinary terbutaline excreted from COPD patients (A) 30 min post one
inhalation; (B) over the first 24 h post one inhalation; (C) 30 min post two inhalations; and (D) over the first 24 h post two inhalations
of two doses of 500 mg terbutaline sulphate dosing from the DPI after using a fast and slow inhalation flows.
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amount of terbutaline cumulatively excreted in the urine
post 24 h is an index of the systemic bioavailability of the
inhaled terbutaline.
The amount excreted 30 min and 24 h post dosing using
slow and fast inhalation flows after one inhalation from
healthy subject and COPD patients confirm the flow
dependent dose emission property of the Turbuhaler. This
was expected from the previously shown in vitro FPD24 and
TED flow dependant. The results indicate that the fast
inhalation flow resulted in a significantly higher amount of
urinary terbutaline excretion 30 min and 24 h post dosing
than slow inhalation (p < 0.01), hence better lung deposi-
tion and higher systemic bioavailability. Two Gama scin-
tigraphy studies3,4 have shown similar results that support
the inhalation at fast inhalation flow from a Turbuhaler.
At fast inhalation flow the amount of terbutaline
excreted 30 min and 24 h post dosing were significantly
higher in health volunteers than in COPD patients
(p < 0.001) and the same were observed at slow inhalation
flow (p < 0.05). Since it was previously demonstrated that
Turbuhaler functions well in COPD patients, in stable
disease,25 moderate to sever patients26,27 and in patients
with exacerbations,28 the difference between the healthy
subjects and the COPD patients could be due to inhalation
volume. The inhalation volume that can be produced by the
healthy subject is much higher than that produced by COPD
patient6 which is an important factor for the de-aggrega-
tion of the terbutaline particles from Turbuhaler.18
However after two inhalations there was no significant
difference in theamountexcreted 30 minand24 hpost dosing
between fast and slow inhalation or healthy volunteers and
COPD patients. This is similar to the effect of the two inhala-
tions on the TED shown above especially at inhalation flow 30
and60 Lmin1whichare theflowused for the invivo test.This
support the use of two inhalations when using the Turbuhaler
to increase the dose delivered. The use of the secondinhalation adds a new effort to de-aggregate the particles of
the drug in the Turbuhaler hence resulting in better
deposition.
Nevertheless, the healthy subjects excreted similar
amounts of terbutaline post one and two inhalations using
fast inhalation. This is similar to the in vitro TED at high
inhalation flow (50 and 60 L min1). This suggests that it
would be unnecessary to inhale twice if subject can inhale
at fast inhalation flow with large inhalation volume.
Though, for a patient with a low inspiratory effort and/or
small inhalation volume it would be better to inhale twice
from a DPI with a high resistant like Turbuhaler.
A study by Derom et al. (2007) showed that the severity
of COPD does not seem to affect the lung deposition of
drugs inhaled via Turbuhaler.29 Though the study was per-
formed on COPD patients only and did not contain any
healthy subjects who have different lung calibres. Also they
used one inhalation flow only which was 60 L min1.
It have been previously shown that for some dry powder
devices such as the Accuhaler and Easyhaler the effect of
the inhalation flow is low whilst it is greater for the Tur-
buhaler.2 In addition, the dose delivered from the Tur-
buhaler was generally less than the labeled amount and was
dependent on the inhalation flow.2 An optimal inhalation
flow may have to be achieved through DPIs with high
resistance to be used effectively.2,30 Therefore, Turbuhaler
or any DPI with a high resistant might be unsuitable for
patients with limited inspiratory effort and inhalation
volumes. If those patients have to use Turbuhaler, it would
be better to advice them to inhale each dose twice and as
deep and fast as possible.Conclusion
The in vitro flow dependent dose emission that has been
previously demonstrated for terbutaline sulphate in the
688 M.E. AbdelrahimTurbuhaler above 30 L min1 is more pronounced below this
flow. The flow dependent dose emission results highlight
the need for the Pharmacopoeias to use a variety of inha-
lation flows and volumes rather than one that is equivalent
to pressure drop of 4 kPa and 4 L inhalation volume. The
results are consistent with the most desirable inhalation
flow for use with the Turbuhaler which has been reported to
be 60 L min1.
It is essential to inhale twice and as hard and deep as
possible from each dose for patients with limited inhalation
volumes and poor inspiratory efforts as they may not
receive much benefit from one inhalation. Although it is
possible to identify those patients using an In-Check Dial31
it may be of some value to encourage all patients to inhale
more than once from one dose.
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